Group One Trading’s Aprea Therapeutics APRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$440 Hold
577
﹤0.01% 7331
2025
Q4
$492 Hold
577
﹤0.01% 7811
2025
Q3
$851 Hold
577
﹤0.01% 8084
2025
Q2
$981 Sell
577
-247
-30% -$421 ﹤0.01% 7562
2025
Q1
$1.68K Hold
824
﹤0.01% 7046
2024
Q4
$2.7K Sell
824
-1,336
-62% -$4.46K ﹤0.01% 6640
2024
Q3
$5.94K Hold
2,160
﹤0.01% 5812
2024
Q2
$8.79K Hold
2,160
﹤0.01% 5695
2024
Q1
$14.4K Hold
2,160
﹤0.01% 5646
2023
Q4
$10.2K Hold
2,160
﹤0.01% 6188
2023
Q3
$9.05K Hold
2,160
﹤0.01% 6392
2023
Q2
$6.8K Hold
2,160
﹤0.01% 6577
2023
Q1
$9.61K Sell
2,160
-40
-2% -$295 ﹤0.01% 5952
2022
Q4
$14.2K Buy
2,200
+650
+42% +$6.86K ﹤0.01% 5836
2022
Q3
$20K Sell
1,550
-90
-5% -$1.6K ﹤0.01% 6061
2022
Q2
$24K Sell
1,640
-1,015
-38% -$23.4K ﹤0.01% 6136
2022
Q1
$99K Sell
2,655
-837
-24% -$34.3K ﹤0.01% 5495
2021
Q4
$200K Sell
3,492
-150
-4% -$13.3K ﹤0.01% 5083
2021
Q3
$372K Buy
3,642
+970
+36% +$88.1K ﹤0.01% 4519
2021
Q2
$261K Buy
2,672
+2,622
+5,244% +$242K ﹤0.01% 4931
2021
Q1
$5K Buy
+50
New +$5.83K ﹤0.01% 7225

Other funds holding APRE

Group One Trading's APRE Position: Q1 2026 in Review

Group One Trading held its Aprea Therapeutics (APRE) position steady in Q1 2026 at 577 shares worth $440. The position accounts for ﹤0.01% of the portfolio, ranked #7331.

Group One Trading first reported a position in APRE in Q1 2021 and has held it in 21 quarters since. The position peaked at $372K in Q3 2021. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

  • Group One Trading held 577 shares of Aprea Therapeutics worth $440 as of Q1 2026.
  • Group One Trading left its Aprea Therapeutics share count unchanged in Q1 2026.
  • Aprea Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #7331 holding.
  • Group One Trading first reported a position in Aprea Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Group One Trading's Aprea Therapeutics position peaked at $372K in Q3 2021.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.